Latest Headlines

  1. Cogent Biosciences Announces Submission Of New Drug Application For Bezuclastinib In Gastrointestinal Stromal Tumors (GIST) 4/1/2026

    Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the completion of the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bezuclastinib in patients with Gastrointestinal Stromal Tumors (GIST) who have received prior treatment with imatinib.

  2. Quantum Biopharma Submits Investigational New Drug (IND) Application To United States Food And Drug Administration (FDA) For Lucid-MS Phase Two Clinical Trial In Multiple Sclerosis 4/1/2026

    Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that it has formally submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Lucid-21-302 (Lucid-MS), its new drug candidate for the treatment of multiple sclerosis (MS).

  3. New AI Technology To Speed Drug Development 4/1/2026

    University of Virginia School of Medicine scientists have developed a bold new approach to drug development and discovery that could dramatically accelerate the creation of new medicines.

  4. NJ Bio, Inc. And Ajinomoto Bio Pharma Services Enter Into Collaboration To Strengthen Support For Antibody-Drug Conjugate Development 3/31/2026

    NJ Bio, Inc. ("NJ Bio"), a leading provider of integrated drug discovery and development services and Ajinomoto Bio‑Pharma Services ("Aji Bio‑Pharma"), a leading provider of biopharmaceutical manufacturing services and platform technologies, today announced a research collaboration to expand access to AJICAP™, Aji Bio‑Pharma's site‑specific conjugation platform for NJ Bio's discovery‑stage and early development clients.

  5. Lupin Receives Tentative Approval From U.S. FDA For Sugammadex Injection 3/31/2026

    Global pharma major, Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vial.

  6. OpenProtein.AI Expands Strategic Partnership With Boehringer Ingelheim To Advance AI-Driven Antibody Discovery 3/31/2026

    OpenProtein.AI, a leader in AI-powered protein engineering software, today announced an expansion of its partnership with Boehringer Ingelheim to co-develop specialized antibody discovery and optimization workflows.

  7. Asha Therapeutics Launches As First Atom Therapeutics, A Zero-Shot De Novo Drug Design Company 3/30/2026

    Asha Therapeutics has announced its rebranding as First Atom Therapeutics (“First Atom”), marking the company’s evolution as a zero-shot de novo drug design company using AI-enabled molecular design technology to create transformative medicines for neurodegenerative, neuro-oncological, and rare diseases.

  8. Zymeworks Receives U.S. FDA Fast Track Designation For ZW191, An Frα-Targeting Antibody-Drug Conjugate 3/30/2026

    Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ZW191, an antibody-drug conjugate (ADC) targeting folate receptor-α (FRα), for the treatment of patients with advanced or metastatic platinum-resistant ovarian cancer (PROC).

  9. Insilico Medicine Announces Global R&D Collaboration With Lilly 3/29/2026

    Insilico Medicine, a clinical-stage biotechnology company powered by generative artificial intelligence (AI) and automation, today announced a drug discovery collaboration with Eli Lilly and Company (“Lilly”) that uses Insilico’s AI engine to accelerate the discovery and development of novel therapeutics across multiple therapeutic areas.

  10. Jyong Biotech Updates The Potential Clinical Benefits And Advantages Of Its Plant-Derived Innovative Drug MCS®-2 3/27/2026

    Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today provided an update on the plant-derived innovative drug MCS®-2 of its multiple competitive advantages and its potential clinical benefits in the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).